Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 12/2003

01-12-2003 | Contrast Media

Currently used non-specific extracellular MR contrast media

Authors: M. F. Bellin, M. Vasile, S. Morel-Precetti

Published in: European Radiology | Issue 12/2003

Login to get access

Abstract

Magnetic resonance contrast agents have demonstrated their clinical usefulness in a variety of organs for improved detection of various neoplastic, inflammatory and functional abnormalities. Gadolinium chelates are the most widely used. They are extracellular, non-specific contrast agents. Their use in many clinical indications is justified because, in conjunction with improved imaging techniques, these safe and image-enhancing contrast agents add morphologic and functional information compared with unenhanced MR images. This article describes the commercially available compounds, and summarizes their approval status on the international market regarding indications and doses. Their mechanisms of action, biodistributions, toxicities and tolerance profiles in normal and high-risk patient populations are described. Additionally, this article reviews the specific recommendations by the manufacturers for patients at risk. Finally, their main clinical applications are reviewed.
Literature
1.
Mathur-de Vré R, Lemort M (1995) Biophysical properties and clinical applications of magnetic resonance imaging contrast agents. Br J Radiol 68:225–247PubMed
2.
Shellock FG, Kanal E (1999) Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 10:477–484PubMed
3.
Brash RB (1992) New directions in the development of MR imaging contrast media. Radiology 183:1–11PubMed
4.
Brash RC, Weinmann HJ, Wesbey GE (1984) Contrast enhanced NMR imaging: animal study using gadolinium-DTPA complex. AJR 142:625–630
5.
Van Beers BE, Gallez B, Pringot J (1997) Contrast-enhanced MR imaging of the liver. Radiology 203:297–306PubMed
6.
Rinck PA, Muller RN (1999) Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol 9:998–1004PubMed
7.
Tweedle MF, Wedeking P, Krishan K (1995) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30:372–380PubMed
8.
Oksendal A, Hals P (1993) Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 3:157–165PubMed
9.
Chang C (1993) Magnetic resonance imaging contrast agents. Designs and physiochemical properties of gadodiamide. Invest Radiol 28 (Suppl 1):521–527
10.
Cacheris W, Quay S, Rocklaye S (1980) The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 8:467–481
11.
Harpur E, Worah D, Hals P et al. (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection: a new magnetic resonance imaging contrast agent. Invest Radiol 28:528–543
12.
Tweedle MF, Ealon S, Eckelman W et al. (1988) Comparative chemical structure and pharmacokinetics of MRI contrast agents. Invest Radiol 23 (Suppl 1):236–239
13.
Tweedle MF (1992) Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 27 (Suppl 1):52–56
14.
Runge VM, Parker JR (1997) Worldwide clinical safety assessment of gadoteridol injection: an update. Eur Radiol 7 (Suppl 5):243–245PubMed
15.
Nelson KI, Gifford LM, Lauber-Huber C, Gross CA, Lasser TA (1995) Clinical safety of gadopentetate dimeglumine. Radiology 2:349–443
16.
Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W (1991) Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med 22:222–228PubMed
17.
Kanal E, Applegate G, Gillen C (1990) Review of adverse reactions, including anaphylaxis in 5260 cases receiving gadolinium-DTPA by bolus injection. Radiology 177:159
18.
Tweedle MF (1997) The proHance story: the making of a novel MRI contrast agent. Eur Radiol 7 (Suppl 5):S225–S230
19.
Yuh WTC, Parker JR, Carvlin MJ (1997) Indication-related dosing for resonance contrast media. Eur Radiol 7 (Suppl 5):S269–S275
20.
Yuh WTC, Nguyen HD, Tali ET et al. (1994) Delineation of gliomas with various doses of MR contrast material. Am J Neuroradiol 15:983–989
21.
Prince MR (1998) Contrast-enhanced MR angiography: theory and optimization. Magn Reson Imaging Clin North Am 6:257–267
22.
Haustein J, Laniado M, Niendorf HP et al. (1993) Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186:855–860PubMed
23.
Yuh WTC, Fisher DJ, Engelken JD et al. (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485–491PubMed
24.
Szopinski K, Szopinska M, Borowka A, Jakubovski W (2000) Magnetic resonance urography: initial experience of a low dose Gd-DTPA-enhanced technique. Eur Radiol 10:1158–1164PubMed
25.
Olukotun AY, Parker JR, Meeks MJ, Lucas MA, Fowler DR, Lucas TR (1995) Safety of gadoteridol injection: US clinical trial experience. J Magn Reson Imaging 5:17–25PubMed
26.
Cohan RH, Leder RA, Herzberg AJ et al. (1991) Extravascular toxicity of two magnetic resonance contrast agents: preliminary experience in the rat. Invest Radiol 26:224–226PubMed
27.
Murphy KJ, Brunberg JA, Cohan RH (1996) Adverse reaction to gadolinium constrast media: a review of 36 cases. AJR 167:847–849
28.
Niendorf HP, Alhassan A, Haustein J, Clauss W, Cornelius I (1993) Safety and risk of gadolinium-DTPA: extended clinical experience after more than 5,000,000 applications. Adv MRI Contrast 2:12–19
29.
Runge VM (2000) Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 12:205–213CrossRefPubMed
30.
Eldevik OP, Brunberg JA (1994) Gadopentetate dimeglumine-enhanced MR of brain: clinical utility and safety in patients younger than two years of age. AJNR 15:1001–1008
31.
Hanquiret S, Christope C, Greef DD, Gordon P, Perlemuller N (1996) Clinical evaluation of gadodiamide injection in pediatric MR imaging. Pediatric Radiol 26:806–810
32.
Niess AC, Le Mignon MM, Vitry A, Caille JM (1991) Efficacité et tolérance du DOTA-Gd lors d'une enquête multicentrique européenne. Rev Im Med 3:383–387
33.
Ball WJ, Nadel S, Zimmerman R et al. (1993) Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 186:769–774PubMed
34.
Yoshikawa K, Davies A (1997) Safety of ProHance in special population. Eur Radiol 7 (Suppl 5):246–250CrossRef
35.
Haustein J, Niendorf H, Krestin G et al. (1992) Renal tolerance of gadolinium-DTPA dimeglumine in patients with chronic renal failure. Invest Radiol 27:153–156
36.
Bellin MF, Deray G, Assogba U et al. (1992) Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10:115–118PubMed
37.
Tombach B, Bremer C, Reimer P et al. (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 218:651–657PubMed
38.
Tombach B, Heindel W (2002) Value of 1.0 M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 12:1550–1556PubMed
39.
Tombach B, Bremer C, Reimer P et al. (2002) Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR 178:105–109PubMed
40.
Schmiedl U, Maravilla K, Gerlach R, Dowling C (1990) Excretion of gadopentetate dimeglumine in human breast milk. AJR 154:1305–1306
41.
Rojski N, Weinreb J, Lih A (1993) Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging 3:131–132PubMed
42.
Kubik-Huch RA, Gottstein NM, Frenzel T et al. (2000) Gadopentetate dimeglumine excretion into human breast milk during lactation. Radiology 216:555–558PubMed
43.
Colosimo C, Manfredi R, Tartaglione T (1997) Contrast-enhanced issues in the MR evaluation of the central nervous system. Eur Radiol 7 (Suppl 5):231–237PubMed
44.
Hamm B, Thoeni RF, Gould RG et al. (1994) Focal liver lesions: characterization with nonenhanced and dynamic contrast-material-enhanced MR imaging. Radiology 190:417–423PubMed
45.
Bartolozzi C, Lencioni R, Donati F, Cioni D (1999) Abdominal MR: liver and pancreas. Eur Radiol 9:1496–1512PubMed
46.
Delorme S, Knopp MV (1998) Non-invasive vascular imaging: assessing tumour vascularity. Eur Radiol 8:517–527PubMed
47.
Ho KY, Leiner T, de Haan MW, van Engelshoven JM (1999) Peripheral MR angiography. Eur Radiol 9:1765–1774PubMed
48.
Mahfouz AE, Hamm B, Taupitz M (1997) Contrast agents for MR imaging of the liver: a clinical overview. Eur Radiol 7:507–513CrossRefPubMed
49.
Saeed M, Higgings CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR agents in normal and acutely reperfused infarcted myocardium using echo-planar MR imaging. Eur Radiol 10:310–318PubMed
50.
Sze G, Stimac GK, Barlett C et al. (1990) Multicenter study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with spinal tumors. AJNR 11:967–974
51.
Yamashita Y, Mitsuzaki K, Yi T et al. (1996) Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 200:79–84PubMed
52.
Oi H, Mukarami T, Kim T et al. (1996) Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 166:369–374
53.
Scialpi M, Maggio A di, Midiri M, Loperfido A, Angelelli G, Rotondo A (2000) Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression. AJR 175:751–757
54.
Balci NC, Semelka RC, Patt RH et al. (1999) Complex renal cysts: findings on MR imaging. AJR 172:1495–1500
55.
Saez F, Urresola A, Larena JA et al. (2000) Endometrial carcinoma: assessment of myometrial invasion with plain and gadolinium-enhanced MR imaging. J Magn Reson Imaging 12:460–466CrossRefPubMed
56.
Kinoshita T, Ishii K, Naganuma H, Higashiiwai H (2000) MR findings of ovarian tumours with cystic components. Br J Radiol 73:333–339PubMed
57.
Barentsz JO, Engelbrecht M, Jager GJ et al. (1999) Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 10:295–304PubMed
58.
Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J (2000) A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. Br J Urol 85:32–36
59.
Glockner JF (2001) Three-dimensional gadolinium-enhanced MR angiography: applications for abdominal imaging. RadioGraphics 21:357–370PubMed
60.
White-Nunes L, Schnall MD, Orel SG et al. (1999) Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model. RadioGraphics 19:79–92PubMed
61.
Fisher U, Kopka L, Grabbe E (1999) Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic apprach. Radiol 213:881–888PubMed
62.
Hulka CA, Edmister WB, Smith BL et al. (1997) Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837–842PubMed
63.
van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL (1998) Musculoskeletal tumors: Does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 208:821–828
Metadata
Title
Currently used non-specific extracellular MR contrast media
Authors
M. F. Bellin
M. Vasile
S. Morel-Precetti
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
European Radiology / Issue 12/2003
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-003-1912-x

Other articles of this Issue 12/2003

European Radiology 12/2003 Go to the issue

Physics

Synchrotron radiation in radiology: novel X-ray sources

Interpretation Corner

An interesting hepatic mass: splenosis mimicking a hepatocellular carcinoma (2003:9b)

Gastrointestinal

Outcome of acute nonvariceal gastrointestinal haemorrhage after nontherapeutic arteriography compared with embolization

Pediatric

Bronchopulmonary foregut malformations: embryology, radiology and quandary

News of the EAR

Trends in radiology in Finland between 1995 and 2000

Letter to the Editor

Reply